The rationale for pathogen-inactivation treatment of blood components

International Journal of Hematology

Volumn 80, Issue 4, 2004, Pages 311-316

  Barbara, John A J ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b Microbiol Consult Natl Blood S   (United Kingdom)

Author keywords

Emerging agents; Pathogen inactivation; Product liability; Residual risk; Window period

Indexed keywords

BABESIOSIS; BACTERIUM CULTURE; BLOOD DONOR; BLOOD TRANSFUSION; CHAGAS DISEASE; CREUTZFELDT JAKOB DISEASE; HEPATITIS B VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MALARIA; NUCLEIC ACID ANALYSIS; PARVOVIRUS; POSTTRANSFUSION HEPATITIS; REVIEW; SAFETY; SERODIAGNOSIS; SYPHILIS; TOXOPLASMOSIS; TRANSFUSION TRANSMITTED INFECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BACTERIAL INFECTIONS; BLOOD BANKS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS; RISK FACTORS; VIRUS DISEASES;

EID: 9444293510     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04120     Document Type: Review

References (16)

1. Barbara JAJ. Microbiology in Blood Transfusion. Bristol, UK: John Wright; 1983.
2. MMWR. Update: detection of West Nile virus in blood donations: United States, 2003. MMWR [serial online]. 2003;52(Dispatch):1-3. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm52d918a1.htm. Accessed September 14, 2004.
3. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion. 2001;41:560-569.
4. Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-1 in blood donations after leukocyte depletion. Blood. 2002;100: 677-681.
5. Barbara JAJ, Eglin R, eds. Nucleic acid amplification technology for blood donor screening. Transfus Med. 2002;12(theme issue):227-285.
6. Simmonds P, Kurtz J, Tedder RS. The UK blood transfusion service: over a (patent) barrel? Lancet. 2002;359:1713-1714.
7. Barbara JAJ. Why 'safer than ever' may not be quite safe enough. Transfus Med Hemother. 2004;31(suppl 1):2-10.
8. McDonald C, Roy A, Mahajan P, Smith R, Charlett A, Barbara JA. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang. 2004;86:178-182.
9. Barbara JAJ. Evolution of microbial safety. Hematol J. 2004; 5(suppl 3):S69-S73.
10. SHOT Office. Serious hazards of transfusion annual report 2003 [SHOT Web site]. July 5, 2004. Available at: http://www.shot-uk. org/SHOT%20Report%202003. pdf. Accessed September 14, 2004.
11. Schreiber G, Busch M, Kleinman S, Korelitz J. The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685-1690.
12. Soldan K, Barbara JAJ, Ramsay ME, Hall AJ. Estimates of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang. 2003;84:274-286.
13. Hepatitis patients win compensation. BBC News Online. March 26, 2001. Available at: http://news.bbc.co.uk/1/hi/wales/1243239.stm. Accessed September 14, 2004.
14. Jongerius J, Wester M, Cuyper H, et al. New hepatitis B virus mutant form in a blood donors that is undetectable in several hepatitis B surface antigen screening assays. Transfusion. 1998;38: 56-59.
15. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527-529.
16. Mollison PL, Engelfriet CP, Contreras M. Infectious agents transmitted by transfusion. In: Blood Transfusion in Clinical Medicine. London, UK: Blackwell Science; 1997:509-557.